Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738699 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
A Phase 2 study, sponsored by Morphotek.
- Terminated
- Registry status
- Phase 2
- Development phase
- 415
- Enrollment target
NCT00738699 is a Phase 2 study that was terminated before completion, run by Morphotek. The registered enrollment target is 415 participants.
The verdict
NCT00738699, a Phase 2 study, was terminated before completion, sponsored by Morphotek.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 415 participants
- Enrollment target
Study Summary
The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer
Interventions
- DRUG Paclitaxel
- DRUG 0.9% Saline
- DRUG MORAb-003 (farletuzumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00738699
The ClinicalTrials.gov registry entry for NCT00738699 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 415 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT00738699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00738699 about?
NCT00738699 is a clinical study titled "An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer". The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer
What is the current status of trial NCT00738699?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 415 participants. The study started on 2008-09. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00738699?
The interventions under investigation include: Paclitaxel (DRUG), 0.9% Saline (DRUG), MORAb-003 (farletuzumab) (DRUG).
Who is sponsoring clinical trial NCT00738699?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.